Effects of Maintaining Steady Albumin Levels (TAT 4) on Survival and Liver Related Complications in Cirrhosis With Ascites

• Status: Unknown status
• Trial end date: 2021-08-08
• Target enrollment: 0
• Participant gender: All

Summary

Investigators intend to assess the utility of regular albumin infusions to maintain a targeted serum albumin level of 4.0 g/dl in newly detected cirrhotic patients with low albumin levels (<2.8g/dl) with ascites.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Institute of Liver and Biliary Sciences, India

Criteria

Inclusion Criteria:

• Newly detected cirrhotic patients aged more than 18 years

• Cirrhosis defined by standard clinical, analytical and/or histological criteria

• Serum albumin level < 2.8g/dl with or without ascites

• Who would agree to give written informed consent

Exclusion Criteria:

• Uncontrolled HTN (sys>150/ dis >90 mmHg) or h/o any drug therapy for HTN

• Prior h/o Transjugular Intrahepatic Portosystemic Shunt (TIPS)

• Hepatocellular Carcinoma

• Active alcohol abuse within 3 months

• Patients presenting as Acute on Chronic Liver Failure

• Extrahepatic organ failure

• Known case of chronic heart failure or respiratory failure

• Diagnosed Chronic Kidney Disease

• Patients with hydrothorax

• Prior liver transplant recipient

• Human Immunodeficiency Virus infection

• Use of albumin infusion in the last one month

• CTP>12, MELD>28

• Total Bilirubin >3 g/dl

• Overt Hepatic Encephalopathy at Presentation